Immune Design
May 14, 2015

Immune Design Reports First Quarter 2015 Financial Results

Company to Hold Conference Call to Review Financial Results and Provide ASCO Clinical Research Update at 8:30 a.m. Eastern Today

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results for the first quarter ended March 31, 2015.

First Quarter 2015 Highlights

Follow-on Financing

First Quarter 2015 Financial Highlights

Conference Call Information

Immune Design will host a conference call and live audio webcast this morning at 5:30 a.m. PDT/8:30 a.m. EDT to provide a corporate update and discuss its financial results as well as provide an ASCO clinical research update. To participate in the conference call, please dial (844) 831-3023 (domestic) or (920) 663-6275 (international) and refer to conference ID 46914908. To access the live webcast, please visit the "Events & Presentations" page under the "Investors" tab on Immune Design's website at

An archived copy of the webcast will be available on Immune Design's website beginning approximately two hours after the conference call. Immune Design will maintain an archived replay of the webcast on its website for at least 30 days after the conference call.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of initiation, progress and scope of clinical trials for Immune Design's product candidates and the reporting of clinical data regarding Immune Design's product candidates. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrolment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Immune Design
Selected Balance Sheet Data
(In Thousands)
 March 31,December 31,
Cash and cash equivalents  $ 60,230  $ 75,354
Total assets  63,297    78,383
Total Current liabilities  4,976    11,947
Total stockholders' equity  58,248  66,346
Statements of Operation Data (unaudited)
(In Thousands Except Per Share Amounts)
 Three Months Ended
 March 31,
Product sales  $ 89  $ 25
Other, net  1,849  — 
Total revenues  1,938  25
Operating expenses:    
Cost of product sales  79  14
Research and development  7,463  4,078
General and administrative  3,802  1,446
Total operating expenses  11,344  5,538
Loss from operations  (9,406)  (5,513)
Interest and other income  —   1
Change in fair value of convertible preferred stock warrant liability  —   (2,711)
Net loss attributable to common stockholders  $ (9,406)  $ (8,223)
Basic and diluted net loss per share attributable to common stockholders  $ (0.56)  $ (22.25)
Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders  16,944,871  369,656
CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications



         Investor Contact

         Shari Annes

         Annes Associates